Danish Research Foundation, Copenhagen   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Copenhagen Denmark (1991)

Organization Overview

First Clinical Trial
2006
NCT00313105
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Copenhagen University Hospital, Denmark | Danish Research Foundation, FSS, Copenhagen, Denmark

Active Ingredients

Drugs in Phase 4 Trials (3)

acetaminophen (tylenol) (1 trial)

ropivacaine (naropin) (1 trial)

sufentanil (1 trial)

Drugs in Phase 3 Trials (1)

tobacco (1 trial)

Drugs in Phase 2 Trials (2)

cannabidiol (Epidiolex) (1 trial)

risperidone (risperdal) (1 trial)

Drugs in Other Trials (1)

allogeneic blood cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ductal (Phase 4)

Carcinoma in Situ (Phase 4)

Carcinoma, Intraductal, Noninfiltrating (Phase 4)

Psychotic Disorders (Phase 2)

Tobacco Use Disorder (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 7